A股異動 | 大洋生物升停 預計Q1淨利潤同比增113.49%至160.93%
格隆匯4月14日丨大洋生物(003017.SZ)升停,報31.81元,總市值19億元。公司發佈一季度業績預吿,公司預計2023年1-3月業績大幅上升,歸屬於上市公司股東的淨利潤為1800.00萬-2200.00萬,淨利潤同比增長113.49%至160.93%,預計基本每股收益為0.31至0.38元。公司基於以下原因作出上述預測:本報吿期內,歸屬於上市公司股東的淨利潤較上年同期上升113.49%-160.93%,主要系公司主產品碳酸鉀產量、銷量與上年同期相比增幅較大,使單位產品成本費用相應攤薄。同時,去年同期因碳酸鉀原材料價格大幅上升,而產品銷售受行業競爭壓力,價格調整未能同步提升,導致毛利率空間擠壓所致。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.